| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | C L Cooper | |
| R P G van Heeswijk | |||
| P2860 | cites work | Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting | Q33935458 |
| Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals | Q35804046 | ||
| Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. | Q40562633 | ||
| Position paper on therapeutic drug monitoring of antiretroviral agents | Q40637106 | ||
| The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals | Q42627921 | ||
| High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals | Q43646768 | ||
| Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine | Q43860974 | ||
| Liver toxicity caused by nevirapine | Q43864147 | ||
| Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure? | Q44261687 | ||
| Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients | Q44399527 | ||
| Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. | Q44469168 | ||
| Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population | Q44469967 | ||
| Incidence and risk factors for nevirapine-associated rash | Q44550880 | ||
| Race is not associated with nevirapine pharmacokinetics | Q44832985 | ||
| Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study | Q44849439 | ||
| Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial. | Q44850143 | ||
| No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors | Q44905262 | ||
| The relationship between nevirapine plasma concentrations and abnormal liver function tests | Q45016090 | ||
| High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection | Q45789390 | ||
| Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. | Q46818292 | ||
| Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study | Q56791553 | ||
| P433 | issue | 1 | |
| P921 | main subject | nevirapine | Q263713 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 1-7 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | HIV Medicine | Q15756376 |
| P1476 | title | Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review | |
| P478 | volume | 8 |
| Q35771321 | A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy |
| Q90171085 | Adherence to combination antiretroviral therapy among orphaned children in Dar es Salaam, Tanzania |
| Q61439964 | Antiviral drugs |
| Q46398741 | Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. |
| Q30240127 | Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals |
| Q24235724 | Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals |
| Q34975110 | Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals |
| Q35958889 | Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial). |
| Q33720712 | Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes? |
| Q40955419 | Nevirapine Plasma Concentrations in Human Immunodeficiency Virus-Exposed Neonates Receiving High-Dose Nevirapine Prophylaxis as Part of 3-Drug Regimen |
| Q36276839 | Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience |
| Q38038849 | Once-daily nevirapine XR: a brief overview of the safety and efficacy of a new formulation |
| Q34483505 | Population Pharmacokinetics of Nevirapine in HIV-1-Infected Pregnant Women and Their Neonates |
| Q35767808 | QbD-oriented development and validation of a bioanalytical method for nevirapine with enhanced liquid-liquid extraction and chromatographic separation |
| Q35598505 | Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. |
| Q43195215 | Successful viral suppression with subsequent efavirenz-based regimen in HIV-1-infected patients who stop nevirapine prior to discontinuation of the NRTI backbone |
| Q42700015 | Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes |
| Q43027645 | Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients |
| Q51051365 | Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine. |
Search more.